Diagnosis and current treatment of neurological paraneoplastic syndromes

Clinical and Translational Oncology

Volumn 8, Issue 11, 2006, Pages 796-801

  Molina Garrido, María José ^a,c   Guillén Ponce, Carmen ^a   Martínez, Salvador ^b   Guirado Risueño, María ^a  

^a University General Hospital   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Autoantibodies; Immunotherapy; Paraneoplastic syndromes

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PLACEBO; PREDNISONE; PROTEIN ANTIBODY; TACROLIMUS; AUTOANTIBODY; CANCER ANTIBODY;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; AUTOIMMUNITY; BRAIN METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER LOCALIZATION; CANCER PATIENT; CELLULAR IMMUNITY; CEREBROSPINAL FLUID EXAMINATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EARLY INTERVENTION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; LABORATORY TEST; LYMPHOCYTIC INFILTRATION; MYASTHENIA GRAVIS; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARANEOPLASTIC NEUROPATHY; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; SYMPTOMATOLOGY; T LYMPHOCYTE; TREATMENT OUTCOME; BLOOD; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY;

ANTIBODIES, NEOPLASM; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PLASMAPHERESIS;

EID: 39049193123     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0134-5     Document Type: Review

References (43)

1. Dropcho EJ, Remote neurologic manifestations of cancer. Neurol Clin. 2002;20:85-122.
2. Sute T, Leffers P, Ten Velde G, et al. Neurologic disorders cell lung carcinoma. Cancer. 2004;100:801-6.
3. Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol. 2002;27:384-7.
4. Gatti G, Simsek S, Kurne A, et al. Paraneoplastic neurological disorders in breast cancer. The Breast. 2003;12:203-7.
5. Graus F, Delattre JY, Antonie JG, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135-40.
6. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349:1543-54.
7. Dalmau JO, Posner JB. Paraneoplastic syndromes. Arch Neurol. 1999;56:405-8.
8. Mowzoom N, Bradley WG. Successful immunosuppressant therapy of severe progressive cerebellar degeneration and sensory neuropathy: A case report. J Neurol Sci. 2000;178:63-5.
9. Dalman J, Gultekin HS, Posner JB, Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. Brain Pathol 1999;9:275-84.
10. Dropcho EJ. Update on paraneoplastic syndromes. Curr Opin Neurol. 2005;18: 331-6.
11. Peterson K, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: A clinical analysis of 55 anti-Yo positive patients. Neurology. 1992;42:1031-937.
12. Mason WP, Dalmau J, Curtin JP, et al. Normalization of the tumor marker CA-125 after oophorectomy in a patient with paraneoplastic cerebellar degeneration without detectable cancer. Gynecol Oncol. 1997;65:173-6.
13. Antoine JC, Cinotti L, Tilikete C, et al. (18F)fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol. 2000;48:105-8.
14. Younes-Mhenni S, Janier MD, Cinotti L, et al. FDG-PET improves tumour detection in patients with parameoplastic neurological syndromes. Brain. 2004;127(10):2331-8.
15. Luchinetti CF, Kimmel DW, Lennon V. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear antibodies. Neurology. 1998;50:652-7.
16. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival. J Clin Oncol. 1997;15(8):2866-72.
17. Cartalat-Carel S, Camdessanche JP, Ricard D, et al. The paraneoplastic neurological syndrome associated with anti-CV2 (anti-CRMP5) antibodies is different from that of anti-Hu antibodies. Neurology. 2004;628Suppl 5:A476-A477.
18. Honnorat J, Cartalat-Carel S. Advances in parameoplastic neurological syndromes. Curr Opin Oncol. 2004;16:614-20.
19. Tschernatsch M, Stoltz E, Strittmatter M, et al. Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: Clinical and immunological data. J Neurol Neurosurg Psychiatry. 2005;76(12):1702-6.
20. Mason WP, Graus F, Lang B, et al. Small cell lung cancer, parameoplastic cerebellar degeneration and the Lambert-Eaton mysthenic syndrome. Brain. 1997;120:1279-300.
21. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 2000;55:715-5.
22. Bernal F, Shamsili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology. 2005;60:230-4.
23. Smitt PS, Kinoshita A, de Leeuw B, et al. Paraneoplastic cerebellar ataxia due tu autontibodies against a glutamate receptor. N Engl J Med. 2000(1):342:21-7.
24. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831-44.
25. Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonusmyoclonus syndrome. Ann Neurol. 2003;53:347-53.
26. Graus F, Keime-Guibert F, René R, et al. Anti-Hu associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain. 2001;124:1158-48.
27. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autonatibody type 2: Paraneoplastic accompaniments. Ann Neurol. 2003;55:580-7.
28. Shiraga S, Adamus G. Mechanism of CAR syndrome: Anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9-and caspase 3-dependent pathway. J Neuroimmunol. 2002;132:72-82.
29. Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol. 1998;44:976-80.
30. Newssom-Davis J. Lambert-Easton myasthenic syndrome. Rev Neurol (Paris) 2004;160:177-80.
31. De Giorgo R, Bovara M, Barbara G, et al. Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology. 2003;125(1):70-9.
32. De Giorgio R, Guerrini S, Barbara G, et al. Inflammatory neuropathies of the enteric nervous system. Gastroenterology. 2004;126:1872-83.
33. Ansart J, Nagabhushan N, Syed R, et al. Sinall cell lung cancer associated with anti-Hu paraneoplastic sensory neuropathy and peripheral nerve microvasculitis: Case report and literature review. Clin Oncol (R Coll Radiol). 2004;16(1):71-6.
34. Sorhaug S, Steinshamn SL, Waldum HL, Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC. Lung Cancer. 2005;48(1):137-40.
35. Petzold GC, Marcucci M, Butler MH, et al. Rhabdomyolysis and paraneoplastic stiffman syndrome with amphiphysin autoimmunity. Ann Neurol. 2004;55:286-90.
36. Widdess-Walsh P, Tavee JO, Schuele S, et al. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: Case report and review of the literature. J Neurooncol. 2005;63(2):187-90.
37. Léger JM, Chassande B, Mussel L, et al. Intravenous immunoglobulin therapy in multifocal motorneuropathy. A double-blind, placebo-controlled study. Brain. 2001;124:145-53.
38. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68:489-82.
39. Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neurooncol. 2004;6(1):55-62.
40. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47:9-17.
41. Veneselli E, Conte M, Biancheri R, et al. Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol. 1998;30:15-7.
42. Armstrong MB, Robertson PL, Castle VP. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol. 2005;33:365-7.
43. Byrne T, Mason WP, Posner JB, et al. spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry. 1997, p. 276-8.